Insider · CIK 0001587074
Vuong Trieu
Files at OTLC (Oncotelic Therapeutics, Inc.). First filing Nov 26, 2024, latest Jul 2, 2026.
In brief
Vuong Trieu files SEC Form 4 as CEO, chair, director and 10% owner at OTLC (Oncotelic Therapeutics, Inc.). Since Nov 26, 2024, Vuong Trieu has reported 5 open-market buys worth $46k and 0 open-market sells worth $0, the latest filed on Jul 2, 2026.
A track record needs three past buys with six months of prices behind them; Vuong Trieu has 2, so none is measured yet.
The newest scored trade: bought $10k of OTLC on Jul 1, 2026, filed Jul 2, 2026, scored 41 (moderate). In the last 12 months: 3 buys worth $37k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OTLC: Oncotelic Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Oncotelic Therapeutics, Inc. | $10k 240,000 shares | +0% | +33% from low-64% from high | |
| 41Moderate | Oncotelic Therapeutics, Inc. | $11k 255,000 shares | +0% | +67% from low-55% from high | |
| 36Weak | Oncotelic Therapeutics, Inc. | $15k 335,759 shares | +0% | +33% from low-64% from high | |
| 24Weak | OTLCbuy Oncotelic Therapeutics, Inc. | $994 198,737 shares | +0% | +150% from low-29% from high | |
| 20Weak | OTLCbuy Oncotelic Therapeutics, Inc. | $8,627 298,499 shares | +0% | - |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | OTLC Oncotelic Therapeutics, Inc. | AGrant or award Restricted stock Unitsderivative | +2,000 | $0.00 | $0 | 2,000 | Jul 14, 2026 |
| Jul 1, 2026 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +240,000 | $0.04 | $10k | 94,124,319 | Jul 2, 2026 |
| Jun 24, 2026 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +115,000 | $0.05 | $5,175 | 93,884,319 | Jun 24, 2026 |
| Jun 23, 2026 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +75,000 | $0.05 | $3,375 | 93,769,319 | Jun 24, 2026 |
| Jun 22, 2026 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +65,000 | $0.05 | $2,925 | 93,694,319 | Jun 24, 2026 |
| Jun 17, 2026 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +239,759 | $0.04 | $11k | 93,629,319 | Jun 17, 2026 |
| Jun 15, 2026 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +96,000 | $0.05 | $4,320 | 93,389,560 | Jun 17, 2026 |
| Jan 22, 2026 | OTLC Oncotelic Therapeutics, Inc. | AGrant or award Series A Convertible Preferred Stockderivative | +4,426 | $0.00 | $0 | 8,491 | Jan 26, 2026 |
| Nov 17, 2025 | OTLC Oncotelic Therapeutics, Inc. | AGrant or award Series A Convertible Preferred Stockderivative | +4,065 | $0.00 | $0 | 4,065 | Nov 19, 2025 |
| Jul 10, 2025 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +104,000 | $0.01 | $520 | 93,293,560 | Jul 10, 2025 |
| Jul 9, 2025 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +1 | $0.01 | $0 | 93,293,561 | Jul 10, 2025 |
| Jul 8, 2025 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +94,736 | $0.01 | $474 | 93,388,297 | Jul 10, 2025 |
| Nov 22, 2024 | OTLC Oncotelic Therapeutics, Inc. | POpen-market purchase Common Stock | +298,499 | $0.03 | $8,627 | 92,842,716 | Nov 26, 2024 |
Questions about Vuong Trieu
Answered from the filings on this page, as of the latest one.
Is Vuong Trieu buying or selling?
In the last 12 months Vuong Trieu reported 3 open-market buys worth $37k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $10k of OTLC on Jul 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Vuong Trieu's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Vuong Trieu has 2.
Where does Vuong Trieu file Form 4?
Vuong Trieu has filed Form 4 at OTLC (Oncotelic Therapeutics, Inc.) as CHAIRMAN AND CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.